Latest & greatest articles for Peptic Ulcer Disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Peptic Ulcer Disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Peptic Ulcer Disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Peptic Ulcer Disease

1. Peptic ulcer disease

Peptic ulcer disease Peptic ulcer disease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Peptic ulcer disease Last reviewed: February 2019 Last updated: February 2019 Summary Peptic ulcers usually present as chronic, upper abdominal pain related to eating a meal (dyspepsia). Use of non-steroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori infection are the most common causes. There may be some (...) , bicarbonate, mucosal blood flow). History and exam abdominal pain 'pointing sign' epigastric tenderness nausea or vomiting early satiety weight loss or anorexia diarrhoea symptoms of anaemia gastrointestinal (GI) bleeding hypotensive or septic shock succussion splash Helicobacter pylori infection non-steroidal anti-inflammatory drug (NSAID) use smoking increasing age personal history of peptic ulcer disease family history of peptic ulcer disease patient in intensive care Diagnostic investigations

2019 BMJ Best Practice

2. Peptic ulcer disease

Peptic ulcer disease Peptic ulcer disease - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Peptic ulcer disease Last reviewed: February 2019 Last updated: February 2019 Summary Peptic ulcers usually present as chronic, upper abdominal pain related to eating a meal (dyspepsia). Use of non-steroidal anti-inflammatory drugs (NSAIDs) and Helicobacter pylori infection are the most common causes. There may be some (...) , bicarbonate, mucosal blood flow). History and exam abdominal pain 'pointing sign' epigastric tenderness nausea or vomiting early satiety weight loss or anorexia diarrhoea symptoms of anaemia gastrointestinal (GI) bleeding hypotensive or septic shock succussion splash Helicobacter pylori infection non-steroidal anti-inflammatory drug (NSAID) use smoking increasing age personal history of peptic ulcer disease family history of peptic ulcer disease patient in intensive care Diagnostic investigations

2018 BMJ Best Practice

3. Profile of peptic ulcer disease and its risk factors in Arar, Northern Saudi Arabia (PubMed)

Profile of peptic ulcer disease and its risk factors in Arar, Northern Saudi Arabia Peptic ulcer disease is a multifactorial health problem, and its prevalence and risk factors have changed considerably within the past century.To determine the prevalence of peptic ulcer among the population of Arar city and to identify risk factors for peptic ulcer and to estimate their relative impact on ulcer incidence.A cross-sectional study was carried out on the population of Arar city, Northern Saudi (...) Arabia from November 01, 2016 to April 30, 2017. Data were analyzed by SPSS version 16, using descriptive statistics, prevalence, and Chi-square test.Total prevalence of peptic ulcer among the studied respondents was thus: 21.9% had peptic ulcer; 16.2% gastric ulcer and 5.6% duodenal ulcer. In 19.7% of the cases, the pain was severe, 92.4% reported that pain was precipitated by certain food. In addition to heartburn, 78.8% reported loss of appetite, 71.2% indigestion, 66.7% regurgitation, 59.1

Full Text available with Trip Pro

2017 Electronic physician

4. Peptic ulcer disease. (PubMed)

Peptic ulcer disease. The rapidly declining prevalence of Helicobacter pylori infection and widespread use of potent anti-secretory drugs means peptic ulcer disease has become substantially less prevalent than it was two decades ago. Management has, however, become more challenging than ever because of the threat of increasing antimicrobial resistance worldwide and widespread use of complex anti-thrombotic therapy in the ageing population. Peptic ulcers not associated with H pylori infection (...) or the use of non-steroidal anti-inflammatory drugs are now also imposing substantial diagnostic and therapeutic challenges. This Seminar aims to provide a balanced overview of the latest advances in the pathogenetic mechanisms of peptic ulcers, guidelines on therapies targeting H pylori infection, approaches to treatment of peptic ulcer complications associated with anti-inflammatory analgesics and anti-thrombotic agents, and the unmet needs in terms of our knowledge and management of this increasingly

2017 Lancet

6. Process of care and outcomes for elderly patients hospitalized with peptic ulcer disease: results from a quality improvement project. (PubMed)

Process of care and outcomes for elderly patients hospitalized with peptic ulcer disease: results from a quality improvement project. Since publication in 1994 of guidelines for management of peptic ulcer disease (PUD), trends in physician practice and outcomes related to guideline application have not been evaluated.To describe changes in process of care that occurred in a quality improvement program for patients hospitalized with PUD and to evaluate associations between in-hospital treatment

2017 JAMA

7. A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease

A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease A systematic review of the comparative effectiveness of proton pump inhibitors for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease | Therapeutics Initiative Independent Healthcare Evidence > > A systematic review of the comparative effectiveness of proton pump inhibitors (...) for the treatment of adult patients with gastroesophageal reflux disease or peptic ulcer disease This was produced by the Drug Assessment Working Group of the Therapeutics Initiative at the request of the Pharmaceutical Services Division (PSD) of the British Columbia Ministry of Health as part of the Drug Effectiveness Review Project (DERP), a class review of proton pump inhibitors (PPIs) for the treatment of adult patients with symptomatic GERD or PUD. Research questions Four research questions were

2016 Therapeutics Letter

8. Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. (PubMed)

Eradication therapy for peptic ulcer disease in Helicobacter pylori-positive people. Peptic ulcer disease is the cause of dyspepsia in about 10% of people. Ninety-five percent of duodenal and 70% of gastric ulcers are associated with Helicobacter pylori. Eradication of H. pylori reduces the relapse rate of ulcers but the magnitude of this effect is uncertain. This is an update of Ford AC, Delaney B, Forman D, Moayyedi P. Eradication therapy for peptic ulcer disease in Helicobacter pylori (...) from conference proceedings from the United European Gastroenterology Week (published in Gut) and Digestive Disease Week (published in Gastroenterology). The search was last updated in March 2016. We contacted members of Cochrane Upper GI and Pancreatic Diseases, and experts in the field and asked them to provide details of outstanding clinical trials and any relevant unpublished materials.We analysed randomised controlled trials of short- and long-term treatment of peptic ulcer disease in H

Full Text available with Trip Pro

2016 Cochrane

9. [Peptic ulcer disease and Helicobacter pylori. A comparative study of two different three-drug regimens]. (PubMed)

[Peptic ulcer disease and Helicobacter pylori. A comparative study of two different three-drug regimens]. Helicobacter pylori (H. pylori) is now known to be strongly associated with gastritis type B, duodenal ulcer, gastric ulcer and perhaps gastric cancer. To cure peptic ulcer disease has become reality. This prospective study included 60 patients, 41 male and 19 females, with long history of peptic ulcer disease (1 - 41 yr, mean 16.5 yr), diagnosed with active duodenal ulcer (50) or gastric (...) at 12 months follow-up. No ulcer recurrence occured in H. pylori negative patients. The importance of persistent and marked symptomatic improvement observed in this study as compared to conventional maintenance treatment has not been emphasized enough in the recent debates on ulcer treatment modalities. The ultimate benefit of H. pylori eradication in peptic ulcer disease should be evaluated by long term follow up studies..

2015 Laeknabladid

10. Non-Surgical Periodontal Therapy Can Reduce the Reinfection Rate of Helicobacter pylori in Patients Suffering from Peptic Ulcer Disease

Non-Surgical Periodontal Therapy Can Reduce the Reinfection Rate of Helicobacter pylori in Patients Suffering from Peptic Ulcer Disease UTCAT2763, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Non-Surgical Periodontal Therapy Can Reduce the Reinfection Rate of Helicobacter pylori in Patients Suffering from Peptic Ulcer Disease Clinical Question In patients diagnosed with peptic ulcer disease, will non-surgical (...) periodontal therapy reduce Helicobacter pylori gastric reinfection rates? Clinical Bottom Line Patients with peptic ulcer disease experience lower H. pylori reinfection rates when treated with nonsurgical periodontal therapy in addition to anti-H. pylori therapy. This is supported by a systematic review of three included studies showing significantly lower rates of gastric infection over time in patients receiving periodontal therapy. Best Evidence (you may view more info by clicking on the PubMed ID link

2014 UTHSCSA Dental School CAT Library

11. Second-look endoscopy for bleeding peptic ulcer disease: a decision-effectiveness and cost-effectiveness analysis

Second-look endoscopy for bleeding peptic ulcer disease: a decision-effectiveness and cost-effectiveness analysis Second-look endoscopy for bleeding peptic ulcer disease: a decision-effectiveness and cost-effectiveness analysis Second-look endoscopy for bleeding peptic ulcer disease: a decision-effectiveness and cost-effectiveness analysis Imperiale TF, Kong N Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract (...) was usually performed within 16 to 24 hours of the first endoscopy, and could be followed by surgery. Location/setting USA/secondary care. Methods Analytical approach: A decision tree was developed for the pathway of patients after a first endoscopy to treat bleeding in peptic ulcer disease. Patients who were assigned to no second endoscopy could have a second endoscopy if bleeding recurred. Second endoscopies could result in bleeding, complications, surgery, or death. The authors stated

Full Text available with Trip Pro

2012 NHS Economic Evaluation Database.

12. Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease (PubMed)

Systematic review of the symptom burden, quality of life impairment and costs associated with peptic ulcer disease Management of peptic ulcer disease has improved over the past few decades. However, the widespread use of nonsteroidal anti-inflammatory drugs and low-dose acetylsalicylic acid means that the burden of peptic ulcer disease remains a relevant issue.We systematically searched PubMed and EMBASE for articles published 1966-2007 that reported symptoms, impairment of well-being or health (...) -related quality of life, and costs associated with peptic ulcer disease.Thirty studies reported the prevalence of patient-reported gastrointestinal symptoms in individuals with endoscopically diagnosed symptomatic peptic ulcer disease. Average prevalence estimates, weighted by sample size, were 81% (95% confidence interval [CI], 77%-85%) for abdominal pain (11 studies), 81% (95% CI, 76%-85%) for pain specifically of epigastric origin (14 studies), and 46% (95% CI, 42%-50%) for heartburn or acid

2010 EvidenceUpdates

13. The role of endoscopy in the management of patients with peptic ulcer disease

The role of endoscopy in the management of patients with peptic ulcer disease GUIDELINE The role of endoscopy in the management of patients with peptic ulcer disease Thisisoneofaseriesofstatementsdiscussingtheuseof GI endoscopy in common clinical situations. The Stan- dards of Practice Committee of the American Society for Gastrointestinal Endoscopy (ASGE) prepared this text. In preparing this guideline, a search of the medical litera- ture was performed by using PubMed. Additional refer- ences (...) a course of action that varies from this guideline. Upper GI endoscopy has largely replaced upper GI bar- ium x-ray series for the evaluation of upper GI tract dis- ease or symptoms because it allows direct visualization, tissue acquisition, and therapeutic interventions. This guideline is an update of a previous ASGE document 2 and de?nes the roleof upper GI endoscopy in the diagno- sis and management of patients with known or suspected peptic ulcer disease (PUD). THE PATIENT WITH SUSPECTED PUD

2010 American Society for Gastrointestinal Endoscopy

14. Peptic ulcer disease. (PubMed)

Peptic ulcer disease. Peptic ulcer disease had a tremendous effect on morbidity and mortality until the last decades of the 20th century, when epidemiological trends started to point to an impressive fall in its incidence. Two important developments are associated with the decrease in rates of peptic ulcer disease: the discovery of effective and potent acid suppressants, and of Helicobacter pylori. With the discovery of H pylori infection, the causes, pathogenesis, and treatment of peptic ulcer (...) disease have been rewritten. We focus on this revolution of understanding and management of peptic ulcer disease over the past 25 years. Despite substantial advances, this disease remains an important clinical problem, largely because of the increasingly widespread use of non-steroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin. We discuss the role of these agents in the causes of ulcer disease and therapeutic and preventive strategies for drug-induced ulcers. The rare but increasingly

2009 Lancet

15. In Patients with Peptic Ulcer Disease, What Is the Most Accurate Diagnostic Test to Determine the Presence of Helicobacter pylori Prior to Treatment?

In Patients with Peptic Ulcer Disease, What Is the Most Accurate Diagnostic Test to Determine the Presence of Helicobacter pylori Prior to Treatment? "In Patients with Peptic Ulcer Disease, What Is the Most Accurate Diagn" by Jason R. Kwiatkowski < > > > > > Title Author Date of Graduation 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor Mary Von, MS, PA-C Second Advisor Rob Rosenow PharmD, OD Third Advisor Annjanette Sommers MS (...) shown to either have a low accuracy rate or too many variables that can affect the outcome of the test. Recommended Citation Kwiatkowski, Jason R., "In Patients with Peptic Ulcer Disease, What Is the Most Accurate Diagnostic Test to Determine the Presence of Helicobacter pylori Prior to Treatment?" (2009). School of Physician Assistant Studies . 163. https://commons.pacificu.edu/pa/163 DOWNLOADS Since August 13, 2009 Included in Share COinS Browse Search Enter search terms: Select context to search

2009 Pacific University EBM Capstone Project

16. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. (PubMed)

Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Peptic ulcer disease is the cause for dyspepsia in about 10% of patients. 95% of duodenal and 70% of gastric ulcers are associated with Helicobacter pylori. Eradication of H pylori reduces the relapse rate of ulcers but the magnitude of this effect is uncertain.The primary outcomes were the proportion of peptic ulcers healed initially and proportion of patients free from relapse following successful healing (...) materialsRandomised controlled trials of short and long-term treatment of peptic ulcer disease in H. pylori positive adults were analysed. Patients received at least one week of H pylori eradication compared with ulcer healing drug, placebo or not treatment. Trials were included if they reported assessment from 2 weeks onwards.Data were collected on ulcer healing, recurrence, relief of symptoms and adverse effects.63 trials were eligible. Data extraction was not possible in 7 trials, and 56 trials were included

2006 Cochrane

17. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease: a systematic review

Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease: a systematic review Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease: a systematic review Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease: a systematic review Huang J Q, Zheng (...) G F, Hunt R H, Wong W M, Lam S K, Karlberg J, Wong B C CRD summary This review assessed whether patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatment than those with peptic ulcer disease. No convincing evidence for a difference in eradication rate was identified. Despite uncertainty about the quality of the included studies, this was generally a good-quality systematic review and the authors' conclusions are likely to be reliable. Authors' objectives

2005 DARE.

18. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis

Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

19. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. (PubMed)

Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Peptic ulcer disease is the cause for dyspepsia in about 10% of patients. 95% of duodenal and 70% of gastric ulcers are associated with Helicobacter pylori. Eradication of H pylori reduces the relapse rate of ulcers but the magnitude of this effect is uncertain.The primary outcomes were the proportion of peptic ulcers healed initially and proportion of patients free from relapse following successful healing (...) treatment of peptic ulcer disease in H. pylori positive adults were analysed. Patients received at least one week of H pylori eradication compared with ulcer healing drug, placebo or not treatment. Trials were included if they reported assessment from 2 weeks onwards.Data were collected on ulcer healing, recurrence, relief of symptoms and adverse effects.59 trials were eligible. Data extraction was not possible in 7 trials, and 52 trials were included. In duodenal ulcer healing, eradication therapy

2003 Cochrane

20. The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model

The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete-event simulation model The cost-effectiveness of screening for Helicobacter pylori to reduce mortality and morbidity from gastric cancer and peptic ulcer disease: a discrete (...) ulcer disease: a discrete-event simulation model. Health Technology Assessment 2003; 7(6): 1-86 Authors' objectives The objective of the study was to develop a discrete-event simulation model to evaluate the cost-effectiveness of population screening for H. pylori in England and Wales to prevent both gastric cancer and peptic ulcer disease. Authors' conclusions Population screening for H. pylori is likely to be cost-effective with a cost/LYS of under 10,000 GBP for the base assumptions, which

2003 Health Technology Assessment (HTA) Database.